Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes combo drug shows promise in early trial

NCT ID NCT00971243

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested four different doses of a new drug called MP-513 in 448 adults with type 2 diabetes who were already taking metformin. The goal was to see which dose works best and is safe for lowering blood sugar over 24 weeks, with an extension up to 52 weeks. Participants took MP-513 tablets once daily alongside their usual metformin.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MP-513 (a diabetes drug) plus metformin
What this could lead to
If successful, this could provide a new treatment option for people with type 2 diabetes to better control their blood sugar when metformin alone isn't enough.
What could go wrong
This is an early phase II dose-finding study, so the drug may not prove effective or safe enough for approval. Side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

  • Study site

    Aalborg, Denmark

  • Study site

    Ballerup Municipality, Denmark

  • Study site

    Vejle, Denmark

  • Study site

    Falkensee, Germany

  • Study site

    Hamburg, Germany

  • Study site

    Karlsruhe, Germany

  • Study site

    Kiel, Germany

  • Study site

    Ludwigshafen, Germany

  • Study site

    Lübeck, Germany

  • Study site

    Mainz, Germany

  • Study site

    Ádám, Hungary

  • Study site

    Békéscsaba, Hungary

  • Study site

    Budapest, Hungary

  • Study site

    Gyöngyös, Hungary

  • Study site

    Kaposvár, Hungary

  • Study site

    Miskolc, Hungary

  • Study site

    Nyíregyháza, Hungary

  • Study site

    Semmelweis, Hungary

  • Study site

    Szentes, Hungary

  • Study site

    Szigetvár, Hungary

  • Study site

    Kaunas, Lithuania

  • Study site

    Klaipėda, Lithuania

  • Study site

    Vilnius, Lithuania

  • Study site

    Gdansk, Poland

  • Study site

    Krakow, Poland

  • Study site

    Leszno, Poland

  • Study site

    Lodz, Poland

  • Study site

    Niemodlin, Poland

  • Study site

    Płock, Poland

  • Study site

    Warsaw, Poland

  • Study site

    Wroclaw, Poland

  • Study site

    Brasov, Romania

  • Study site

    Bucharest, Romania

  • Study site

    Galati, Romania

  • Study site

    Ploieşti, Romania

  • Study site

    Timișoara, Romania

  • Study site

    Timuș, Romania

  • Study site

    Addlestone, United Kingdom

  • Study site

    Ayr, United Kingdom

  • Study site

    Bournemouth, United Kingdom

  • Study site

    East Sussex, United Kingdom

  • Study site

    Edinburgh, United Kingdom

  • Study site

    Oldham, United Kingdom

  • Study site

    York, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.